Carlos A. Matos

Carlos A. Matos

Auto-generated profile, based on publicly available information

Carlos A. Matos

Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
AMAdriana Marcelo
Adriana Marcelo
RKRebekah Koppenol
Rebekah Koppenol
LALuís Pereira de Almeida
Luís Pereira de Almeida
CMCarlos A. Matos
Carlos A. Matos
CNClévio Nóbrega
Clévio Nóbrega
Stress granules (SGs) are membraneless cell compartments formed in response to different stress stimuli, wherein translation factors, mRNAs, RNA-binding proteins (RBPs) and other proteins coalesce together. SGs assembly is crucial for cell survival, since SGs are implicated in the regulation of translation, mRNA storage and stabilization and cell signalling, during stress. One defining feature of SGs is their dynamism, as they are quickly assembled upon stress and then rapidly dispersed after the stress source is no longer present. Recently, SGs dynamics, their components and their functions have begun to be studied in the context of human diseases. Interestingly, the regulated protein self-assembly that mediates SG formation contrasts with the pathological protein aggregation that is a feature of several neurodegenerative diseases. In particular, aberrant protein coalescence is a key feature of polyglutamine (PolyQ) diseases, a group of nine disorders that are caused by an abnormal expansion of PolyQ tract-bearing proteins, which increases the propensity of those proteins to aggregate. Available data concerning the abnormal properties of the mutant PolyQ disease-causing proteins and their involvement in stress response dysregulation strongly suggests an important role for SGs in the pathogenesis of PolyQ disorders. This review aims at discussing the evidence supporting the existence of a link between SGs functionality and PolyQ disorders, by focusing on the biology of SGs and on the way it can be altered in a PolyQ disease context.

30 June 2018 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
CMCarlos A. Matos
Carlos A. Matos
LALuis Pereira De Almeida
Luis Pereira De Almeida
CNClévio Nóbrega
Clévio Nóbrega
Machado–Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is an incurable disorder, widely regarded as the most common form of spinocerebellar ataxia in the world. MJD/SCA3 arises from mutation of the ATXN3 gene, but this simple monogenic cause contrasts with the complexity of the pathogenic mechanisms that are currently admitted to underlie neuronal dysfunction and death. The aberrantly expanded protein product – ataxin‐3 – is known to aggregate and generate toxic species that disrupt several cell systems, including autophagy, proteostasis, transcription, mitochondrial function and signalling. Over the years, research into putative therapeutic approaches has often been devoted to the development of strategies that counteract disease at different stages of cellular pathogenesis. Silencing the pathogenic protein, blocking aggregation, inhibiting toxic proteolytic processing and counteracting dysfunctions of the cellular systems affected have yielded promising ameliorating results in studies with cellular and animal models. The current review analyses the available studies dedicated to the investigation of MJD/SCA3 pathogenesis and the exploration of possible therapeutic strategies, focusing primarily on gene therapy and pharmacological approaches rooted on the molecular and cellular mechanisms of disease. image

1 September 2011 in Progress in Neurobiology
Verified
Journal Article
Closed access
CMCarlos A. Matos
Carlos A. Matos
SMSandra Macedo-Ribeiro
Sandra Macedo-Ribeiro
ACAna Luísa Carvalho
Ana Luísa Carvalho

14 June 2019 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
CNClévio Nóbrega
Clévio Nóbrega
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
AMAdriana Marcelo
Adriana Marcelo
ALAntonin Lamazière
Antonin Lamazière
STSandra Tomé
Sandra Tomé
SASandro Paiva Fernandes Alves
Sandro Paiva Fernandes Alves

1 January 2019 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
CNCatarina Nunes
Catarina Nunes
IMIsa Mestre
Isa Mestre
AMAdriana Marcelo
Adriana Marcelo
RKRebekah Koppenol
Rebekah Koppenol
CMCarlos A Matos
Carlos A Matos
CNClévio Nóbrega
Clévio Nóbrega
In response to different stress stimuli, cells transiently form stress granules (SGs) in order to protect themselves and re-establish homeostasis. Besides these important cellular functions, SGs are now being implicated in different human diseases, such as neurodegenerative disorders and cancer. SGs are ribonucleoprotein granules, constituted by a variety of different types of proteins, RNAs, factors involved in translation and signaling molecules, being capable of regulating mRNA translation to facilitate stress response. However, until now a complete list of the SG components has not been available. Therefore, we aimer at identifying and linting in an open access database all the proteins described so far as components of SGs. The identification was made through an exhaustive search of studies listed in PubMed and double checked. Moreover, for each identified protein several details were also gathered from public databases, such as the molecular function, the cell types in which they were detected, the type of stress stimuli used to induce SG formation and the reference of the study describing the recruitment of the component to SGs. Expression levels in the context of different neurodegenerative diseases were also obtained and are also described in the database. The Mammalian Stress Granules Proteome is available at https://msgp.pt/, being a new and unique open access online database, the first to list all the protein components of the SGs identified so far. The database constitutes an important and valuable tool for researchers in this research area of growing interest.

14 June 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RCRafael G. Costa
Rafael G. Costa
ACAndré Conceição
André Conceição
CMCarlos A. Matos
Carlos A. Matos
CNClévio Nóbrega
Clévio Nóbrega
A CAG repeat sequence in the ATXN2 gene encodes a polyglutamine (polyQ) tract within the ataxin-2 (ATXN2) protein, showcasing a complex landscape of functions that have been progressively unveiled over recent decades. Despite significant progresses in the field, a comprehensive overview of the mechanisms governed by ATXN2 remains elusive. This multifaceted protein emerges as a key player in RNA metabolism, stress granules dynamics, endocytosis, calcium signaling, and the regulation of the circadian rhythm. The CAG overexpansion within the ATXN2 gene produces a protein with an extended poly(Q) tract, inducing consequential alterations in conformational dynamics which confer a toxic gain and/or partial loss of function. Although overexpanded ATXN2 is predominantly linked to spinocerebellar ataxia type 2 (SCA2), intermediate expansions are also implicated in amyotrophic lateral sclerosis (ALS) and parkinsonism. While the molecular intricacies await full elucidation, SCA2 presents ATXN2-associated pathological features, encompassing autophagy impairment, RNA-mediated toxicity, heightened oxidative stress, and disruption of calcium homeostasis. Presently, SCA2 remains incurable, with patients reliant on symptomatic and supportive treatments. In the pursuit of therapeutic solutions, various studies have explored avenues ranging from pharmacological drugs to advanced therapies, including cell or gene-based approaches. These endeavours aim to address the root causes or counteract distinct pathological features of SCA2. This review is intended to provide an updated compendium of ATXN2 functions, delineate the associated pathological mechanisms, and present current perspectives on the development of innovative therapeutic strategies.